Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support Phase 1 clinical studies of MT-601, its multi-antigen recognizing T cell therapy, in locally advanced unresectable pancreatic cancer. The award represents competitive recognition of the company's MAR-T platform, which has shown a disease control rate of 84.6% in earlier studies. Clinical initiation is anticipated in Q1 2027.